Pentagon funding vaccine to combat airborne Ebola
by: J. D. Heyes
NaturalNews.com
Friday, November 07, 2014
The Defense Department has awarded a pharmaceutical company a multi-million-dollar contract to develop a new Ebola vaccine aimed at combating an airborne version of the Ebola virus.
According to a press release from the company, Profectus BioSciences, Inc., a “clinical-stage vaccine” firm “developing novel vaccines for the treatment and prevention of infectious diseases,” the Pentagon is looking to acquire a new weapon in its arsenal against potential bioweapons, through its Medical Countermeasure Systems-Joint Vaccine Acquisition Program, a division of the DoD’s Joint Program Executive Office for Chemical and Biological Defense in Edgewood, Maryland.
The $9.5 million award will cover “the manufacture and IND-enabling preclinical testing of the Profectus trivalent Ebola/Marburg vaccine,” the press release stated. Also, the Pentagon’s contract covers clinical trials for the VesiculoVaxTM Zaire-Ebola virus vaccine to address the current outbreak of the virus in West Africa.
The Rest…HERE
